Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maverick Trial: Abivertinib + Abiraterone in mCRPC
NCT05361915Phase 2Suspended
- Sponsor
- Sorrento Therapeutics
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abivertinib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sorrento Therapeutics. Primary endpoint: Radiographic Progression-Free Survival at 6 months. Started Sep 2025; status: suspended.
02
Drugs
abivertinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05361915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361915.